We are pleased to inform, that the application for the clinical phase Ib/IIa study TargetAMD_IPE to the Ethical Commission of Geneva, CCER, has been successful. The application was submitted in February 2019 and on April 18th 2019 we received the ethical approval. We are now waiting for the consent of the regulatory authority Swissmedic to […]
9. May 2019
Categories: Target AMD
We are pleased to inform that the 7th TargetAMD peer-reviewed paper was published in Molecular Therapy – Nucleic Acids. Marie Pastor, et al. reported the results of the work package 2 and 3 in which the pFAR4 miniplasmid technique was successfully combined with the Sleeping Beauty transposon system to efficiently and stably transfect eukaryotic and […]
22. February 2018
Categories: Target AMD
Institut de France – Académie des sciences: “The Emilia Valori prize for applied sciences 2017 was awarded to Daniel Scherman, director of the CNRS, Dep. of chemical and biological techniques for health of the pharmaceutical faculty, Paris. His principal field of interest is the gene therapy using synthetic oligonucleotides or bacterial plasmids. He discovered especially […]
11. January 2018
Categories: Target AMD
Results of work package 2 and 3 of the project in which the pFAR4 miniplasmid technique could be successfully combined with the Sleeping Beauty transposon system to efficiently and stably transfect eukaryotic and primary human RPE cells, in particular, is reported in the next peer-reviewed paper of the TargetAMD consortium and was accepted recently for publication […]
12. December 2017
Categories: Target AMD
One paper presenting the transfection of pigment epithelial cells using the novel plasmids has been published in Molecular Therapy: Nucleic Acids (https://www.ncbi.nlm.nih.gov/pubmed/28325297). In the same journal a second paper presents the efficacy of the subretinal transplantation of transfected pigment epithelial cells (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583395/).
1. November 2017
Categories: Target AMD
The TargetAMD consortium will meet in conjunction with the ESGCT XXV anniversary congress in Berlin on October 16, 2017. Latest results and the planning of the last phase of the project will be discussed. Since a special focus lays on the exploitation of TargetAMD results, Dr. Olivier Deloche, member of the UNITEC technology transfer office […]
16. October 2017
Categories: Target AMD
On the upcoming ESGCT congress, the TargetAMD consortium will present recent project results. The coordinator Prof. Dr med. Gabriele Thumann is invited speaker of the session “non-viral gene therapy” and will present an overview of the project. Detailed results will be presented by several posters from Sabine Diarra, UKA, and Dr Martina Kropp, UNIGE, i.a..
29. September 2017
Categories: Target AMD
In the 3rd project period in vitro experiments focused on the establishment of the transfection of low cell numbers of freshly isolated IPE cells and the development of the GMP-compliant production process. The production of the GMP-grade plasmid has been accomplished. Exploitation of developed products and publication of results made significant progress.
12. September 2017
Categories: Target AMD
The Coordinator UNIGE and partner UKA met again with Swissmedic to discuss latest data and their integration in the clinical trial documentation. During this successful presubmission meeting we received very positive feedback from Swissmedic about the presented data and about the planned clinical trial.
29. March 2017
Categories: Target AMD
We are glad to announce that the first TargetAMD manuscript entitled ”Engineering of PEDF‐Expressing Primary Pigment Epithelial Cells by the SB Transposon System Delivered by pFAR4 Plasmids” has been accepted for publication in the international, open access journal Molecular Therapy – Nucleic Acids, an official journal of the American Society of Gene & Cell Therapy […]
17. March 2017
Categories: Target AMD